<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>cardiorenal outcome trials &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/cardiorenal-outcome-trials/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Wed, 14 Oct 2026 00:44:32 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>cardiorenal outcome trials &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>The Hidden Gap Between Percentages and Patients: Why Trial Headlines Mislead Doctors</title>
		<link>https://bioengineer.org/the-hidden-gap-between-percentages-and-patients-why-trial-headlines-mislead-doctors/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Wed, 14 Oct 2026 00:44:32 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[absolute risk reduction]]></category>
		<category><![CDATA[cardiorenal outcome trials]]></category>
		<category><![CDATA[Chronic Kidney Disease]]></category>
		<category><![CDATA[clinical trial reporting]]></category>
		<category><![CDATA[eClinicalMedicine]]></category>
		<category><![CDATA[Evidence-based medicine]]></category>
		<category><![CDATA[GLP-1 receptor agonists]]></category>
		<category><![CDATA[hazard ratio]]></category>
		<category><![CDATA[Major adverse cardiovascular events]]></category>
		<category><![CDATA[number needed to treat]]></category>
		<category><![CDATA[semaglutide]]></category>
		<category><![CDATA[SGLT2 inhibitors]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=418182</guid>

					<description><![CDATA[A new viewpoint in eClinicalMedicine argues that cardiorenal trials should routinely report absolute risk reduction and number needed to treat alongside hazard ratios, because relative measures alone can dramatically overstate the practical benefit patients receive.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">418182</post-id>	</item>
	</channel>
</rss>
